Stock listing
NASDAQ:BIVI BioVie Inc. Stock
Home listing (NASDAQ) of BioVie Inc.
Follow BioVie Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BIVI
$0.80 USD -0.14 (-15.1%)
Close on Nov 20, 2026
- Day range
- $0.752 – $0.91 USDNov 20, 2026
- Volume
- 399,581 sharesNov 20, 2026
- Market cap
- $8.58M USDAt the close on Nov 20, 2026 · price × 10.72M shares outstanding
- 52-week range
- $0.752 – $3.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.96M USDMedian day 250,794 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BIVI · Home | $0.80 USD | -0.143 (-15.1%) | 399,581 | $0.897 | $0.91 | $0.752 | $0.943 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BIVI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.80 | -0.143 | -15.1% | $0.897 | $0.91 | $0.752 | 399,581 | |
| $0.943 | -0.052 | -5.3% | $1.04 | $1.046 | $0.93 | 183,511 | |
| $0.995 | -0.085 | -7.8% | $1.08 | $1.08 | $0.94 | 439,854 | |
| $1.08 | -0.05 | -4.4% | $1.15 | $1.165 | $1.06 | 158,729 | |
| $1.13 | -0.06 | -5.0% | $1.19 | $1.23 | $1.13 | 214,938 | |
| $1.19 | -0.07 | -5.6% | $1.23 | $1.24 | $1.16 | 163,103 | |
| $1.26 | -0.01 | -0.8% | $1.28 | $1.32 | $1.24 | 137,606 | |
| $1.27 | -0.03 | -2.3% | $1.29 | $1.35 | $1.25 | 295,658 | |
| $1.30 | -0.03 | -2.3% | $1.40 | $1.40 | $1.28 | 164,364 | |
| $1.33 | +0.12 | +9.9% | $1.25 | $1.38 | $1.23 | 184,386 | |
| $1.21 | -0.13 | -9.7% | $1.29 | $1.31 | $1.105 | 488,213 | |
| $1.34 | -0.39 | -22.5% | $1.64 | $1.65 | $1.23 | 1,108,131 | |
| $1.73 | +0.36 | +26.3% | $1.45 | $2.66 | $1.40 | 13,523,350 | |
| $1.37 | -0.06 | -4.2% | $1.41 | $1.43 | $1.31 | 120,889 | |
| $1.43 | +0.05 | +3.6% | $1.39 | $1.49 | $1.38 | 105,100 | |
| $1.38 | -0.08 | -5.5% | $1.43 | $1.46 | $1.37 | 41,900 | |
| $1.46 | +0.02 | +1.4% | $1.49 | $1.49 | $1.412 | 106,700 | |
| $1.44 | +0.11 | +8.3% | $1.37 | $1.45 | $1.34 | 195,900 | |
| $1.33 | +0.09 | +7.3% | $1.25 | $1.36 | $1.25 | 139,000 | |
| $1.24 | -0.04 | -3.1% | $1.28 | $1.30 | $1.23 | 141,650 | |
| $1.28 | +0.02 | +1.6% | $1.24 | $1.29 | $1.215 | 101,048 | |
| $1.26 | +0.02 | +1.6% | $1.21 | $1.277 | $1.15 | 195,074 | |
| $1.24 | -0.13 | -9.5% | $1.40 | $1.45 | $1.24 | 279,510 | |
| $1.37 | +0.17 | +14.2% | $1.29 | $1.39 | $1.204 | 182,520 | |
| $1.20 | +0.07 | +6.2% | $1.13 | $1.22 | $1.12 | 275,926 | |
| $1.13 | -0.03 | -2.6% | $1.18 | $1.19 | $1.13 | 166,880 | |
| $1.16 | -0.04 | -3.3% | $1.20 | $1.25 | $1.15 | 342,644 | |
| $1.20 | -0.12 | -9.1% | $1.30 | $1.331 | $1.20 | 171,968 | |
| $1.32 | -0.07 | -5.0% | $1.41 | $1.441 | $1.31 | 67,349 | |
| $1.39 | +0.11 | +8.6% | $1.30 | $1.40 | $1.275 | 204,863 | |
| $1.28 | -0.12 | -8.6% | $1.37 | $1.39 | $1.25 | 362,156 | |
| $1.40 | -0.04 | -2.8% | $1.46 | $1.47 | $1.40 | 134,616 | |
| $1.44 | 0.00 | 0.0% | $1.44 | $1.50 | $1.44 | 132,707 | |
| $1.44 | -0.02 | -1.4% | $1.43 | $1.48 | $1.42 | 135,119 | |
| $1.46 | -0.01 | -0.7% | $1.47 | $1.52 | $1.46 | 189,852 | |
| $1.47 | -0.05 | -3.3% | $1.53 | $1.535 | $1.46 | 266,171 | |
| $1.52 | -0.02 | -1.3% | $1.57 | $1.58 | $1.50 | 201,338 | |
| $1.54 | 0.00 | 0.0% | $1.55 | $1.61 | $1.52 | 146,520 | |
| $1.54 | -0.065 | -4.0% | $1.57 | $1.60 | $1.53 | 182,616 | |
| $1.605 | -0.005 | -0.3% | $1.66 | $1.75 | $1.58 | 458,952 | |
| $1.61 | -0.02 | -1.2% | $1.60 | $1.645 | $1.595 | 235,841 | |
| $1.63 | 0.00 | 0.0% | $1.63 | $1.66 | $1.59 | 216,462 | |
| $1.63 | 0.00 | 0.0% | $1.65 | $1.71 | $1.61 | 201,659 | |
| $1.63 | +0.02 | +1.2% | $1.64 | $1.76 | $1.62 | 411,521 | |
| $1.61 | -0.17 | -9.6% | $1.78 | $1.84 | $1.61 | 406,800 | |
| $1.78 | +0.06 | +3.5% | $1.82 | $1.841 | $1.75 | 478,847 | |
| $1.72 | -0.03 | -1.7% | $1.76 | $1.825 | $1.685 | 439,983 | |
| $1.75 | -0.30 | -14.6% | $1.90 | $1.908 | $1.565 | 1,154,667 | |
| $2.05 | +0.12 | +6.2% | $1.90 | $2.12 | $1.88 | 630,141 | |
| $1.93 | +0.02 | +1.0% | $1.92 | $2.02 | $1.91 | 170,760 | |
| $1.91 | -0.06 | -3.0% | $1.95 | $1.99 | $1.89 | 261,851 | |
| $1.97 | -0.10 | -4.8% | $2.04 | $2.12 | $1.90 | 351,367 | |
| $2.07 | +0.07 | +3.5% | $2.055 | $2.20 | $2.00 | 320,028 | |
| $2.00 | -0.03 | -1.5% | $2.04 | $2.08 | $1.96 | 296,762 | |
| $2.03 | 0.00 | 0.0% | $2.02 | $2.12 | $2.005 | 250,794 | |
| $2.03 | -0.21 | -9.4% | $2.25 | $2.27 | $2.00 | 519,399 | |
| $2.24 | -0.04 | -1.8% | $2.30 | $2.45 | $2.18 | 486,559 | |
| $2.28 | +0.12 | +5.6% | $2.374 | $2.49 | $2.28 | 1,551,930 | |
| $2.16 | -0.03 | -1.4% | $2.20 | $2.25 | $2.106 | 485,693 | |
| $2.19 | +0.08 | +3.8% | $2.09 | $2.22 | $2.00 | 763,384 | |
| $2.11 | +0.02 | +1.0% | $2.005 | $2.25 | $1.967 | 922,448 | |
| $2.09 | -0.05 | -2.3% | $2.00 | $2.11 | $1.93 | 1,029,902 | |
| $2.14 | +0.19 | +9.7% | $1.812 | $2.145 | $1.76 | 2,173,771 | |
| $1.95 | +0.09 | +4.8% | $2.155 | $2.48 | $1.80 | 19,763,840 | |
| $1.86 | +0.52 | +38.8% | $1.545 | $2.39 | $1.49 | 49,110,641 |
Splits
2 splits since 2024 · NASDAQ:BIVI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:BIVI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
Nov 16, 2026
Closed $1.08 (-4.4%) on Nov 16, 2026
BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases
Nov 10, 2026
Closed $1.27 (-2.3%) on Nov 10, 2026
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
Nov 9, 2026
Closed $1.30 (-2.3%) on Nov 9, 2026
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Nov 4, 2026
Closed $1.34 (-22.5%) on Nov 4, 2026
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
Nov 2, 2026
Closed $1.37 (-4.2%) on Nov 2, 2026
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
Oct 26, 2026
Closed $1.33 (+7.3%) on Oct 26, 2026
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
Oct 20, 2026
Closed $1.24 (-9.5%) on Oct 20, 2026
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
Oct 19, 2026
Closed $1.37 (+14.2%) on Oct 19, 2026
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
Oct 14, 2026
Closed $1.16 (-3.3%) on Oct 14, 2026
New to The Street Broadcasts Tonight at 6: 30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
Sep 19, 2026
Closed $1.63 (+1.2%) on Sep 21, 2026
Issued by another party
BioVie Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 120 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 25 decks · latest Oct 23, 2025
Where BioVie Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BIVI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BIVI | BOATS | United States | USD |
Valuation
Price/book 1.3× against a median of 1.0×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.10M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.84
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioVie Inc. · NASDAQ:BIVI | US$8.58M | US$1.10M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.84 |
| PreveCeutical Medical Inc · CSE:PREV | US$8.97M | US$8.95M | n/a | n/a | n/a | n/a | n/a | n/a | 0.73 |
| BioLineRX Ltd. · TASE:BLRX | US$8.90M | US$10.13M | n/a | 8.6× | n/a | 0.5× | −171.7% | 0.3× | n/a |
| CalciMedica, Inc. · NASDAQ:CALC | US$8.69M | US$1.82M | n/a | n/a | n/a | 2.1× | n/a | 1.6× | 0.54 |
| Active Biotech AB · OMXSTO:ACTI | US$8.66M | US$4.38M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | n/a |
| Vyome Holdings, Inc. · NASDAQ:HIND | US$8.42M | US$1.82M | n/a | 11.9× | n/a | 1.3× | n/a | 0.1× | 1.34 |
| CRISM Therapeutics Corporation · LSE:CRTX | US$8.34M | US$5.37M | n/a | 17.8× | n/a | 2.5× | −823.8% | 0.0× | n/a |
| Brainstorm Cell Therapeutics Inc. · OTC:BCLI | US$8.31M | US$10.08M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM | US$8.29M | −US$3.20M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.05 |
| Moleculin Biotech, Inc. · NASDAQ:MBRX | US$8.22M | US$1.04M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.42 |
| IN8bio, Inc. · NASDAQ:INAB | US$8.19M | −US$3.03M | n/a | n/a | n/a | 0.6× | n/a | 0.2× | 1.25 |
| Median of the others | US$8.38M | US$3.10M | 11.9× | 1.0× | −497.8% | 0.1× | 0.73 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.25 USD · Analysts' mean
- EPS, year to Jun 2027
- -0.63 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Cuong Do | President & Chief Executive Officer |
| Wendy Kim | Chief Financial Officer |
| Chris Reading | Senior Vice President Alzheimer's Disease Program |
| Clarence Ahlem | Senior Vice President Operations |
| David Morse | Chief Regulatory Officer and Senior Vice President |
| Joseph M. Palumbo | Executive Vice President, Research & Development and Chief Medical Officer |
| Penelope Markham | Senior Vice President Liver Disease and Long COVID Programs |
Board
| Director | Role |
|---|---|
| Amy Chappell | Independent Director |
| Cuong Do | President & Chief Executive Officer |
| Jim Lang | Independent Director |
| Kameel Farag | Independent Director |
| Michael Sherman | Independent Director |
| Sig Rogich | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 6, 2026 · After close | −2.3% |
| Q4 2026 | Aug 12, 2026 | +22.8% |
| Q3 2026 | Jun 3, 2026 | +1.2% |
| Q2 2026 | Feb 25, 2026 | +1.6% |
| Q1 2026 | Nov 10, 2025 · After close | −3.2% |
| Q4 2025 | Aug 15, 2025 · After close | +6.1% |
| Q3 2025 | May 12, 2025 · After close | −7.0% |
| Q2 2025 | Feb 11, 2025 · After close | −3.9% |
| Q1 2025 | Nov 6, 2024 · After close | +10.0% |
| Q4 2024 | Sep 30, 2024 · After close | −4.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 14, 2024 · After close | −0.8% |
| Q2 2024 | Feb 13, 2024 · Before open | −3.5% |
| Q1 2024 | Nov 8, 2023 · After close | −29.3% |
| Q4 2023 | Aug 16, 2023 · After close | −5.6% |
| Q3 2023 | May 12, 2023 · After close | +0.9% |
| Q2 2023 | Feb 10, 2023 · After close | +2.6% |
| Q1 2023 | Nov 4, 2022 · After close | +0.2% |
| Q4 2022 | Sep 27, 2022 · After close | +8.5% |
| Q3 2022 | May 11, 2022 · After close | −0.8% |
| Q2 2022 | Feb 8, 2022 · Before open | +2.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Longevity Biotech, Boston, MA (October 2025) | Conference | 22 slides | Oct 23, 2025 |
| Investor Presentation (April 2025) | Investor deck | 44 slides | April 2025 |
| 2024 World Congress on Parkinson's Disease and Related Disorders | Conference | 13 slides | May 2024 |
| 12th Annual Alzheimer's and Parkinson's Drug Development Summit 2024 | Conference | 27 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 34 slides | Mar 6, 2024 |
| 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog | Conference | 14 slides | March 2024 |
| ARDD Copenhagen 2024 | Conference | 22 slides | 2024 |
| RedChip Group Investor Webinar December 2023 | Conference | 12 slides | Dec 7, 2023 |
| Technical Presentation (November 2023) | Technical | 13 slides | Nov 29, 2023 |
| Corporate Update (November 2023) | Corporate update | 13 slides | Nov 29, 2023 |
All 25 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock and concurrent private placement common warrants Announced: about US$4.74M · US$1.6 a share · ½ warrant at US$1.7 for 66 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Working capital and general corporate purposes | Nov 4, 2026 |
| Public offering of units (one share of common stock and one warrant) or pre-funded units Closed: US$12M raised · US$2 a unit · 1 warrant at US$2.5 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Working capital and general corporate purposes | Aug 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 229.4K | 229.4K | 266.8K | 237.4K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K | |
| Gross profit | -229.4K | -229.4K | -266.8K | -237.4K | -229.4K | -229.0K | -229.0K | -229.0K | -229.0K | |
| Research and development | 14.0M | 9.27M | 23.1M | 33.3M | 17.3M | 2.54M | 1.15M | 1.01M | 370.9K | 466.4K |
| Selling, general and administrative | 8.51M | 8.57M | 8.85M | 11.6M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 69.1K |
| Operating income | -22.7M | -18.1M | -32.2M | -45.1M | -27.3M | -138.1M | -2.69M | -2.50M | -2.37M | -1.55M |
| Depreciation and amortization | 178.3K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K | 229.4K |
| EBITDA | -22.5M | -17.8M | -32.0M | -44.9M | -27.0M | -137.8M | -2.46M | -2.27M | -2.14M | -1.32M |
| Interest expense | 17.9K | 332.7K | 2.89M | 4.30M | 2.16M | 559.5K | 4.77M | 273 | 41.0K | 222.9K |
| Income before tax | -22.1M | -17.5M | -32.1M | -50.3M | -26.1M | -130.2M | -16.7M | -2.44M | -2.41M | -1.33M |
| Income tax | -229.4K | 4.30M | -3.29M | 559.5K | 4.77M | -51.4K | -1 | -223.0K | ||
| Net income | -22.1M | -17.5M | -32.1M | -50.3M | -26.1M | -130.2M | -16.7M | -2.44M | -2.43M | -1.33M |
| Earnings per share, basic | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 | -14.82 | -6.85 | -0.98 | -0.03 | -0.01 |
| Earnings per share, diluted | -3.05 | -12.12 | -73.05 | -15.47 | -1.06 | -14.82 | -6.85 | -0.98 | -0.03 | -0.01 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.98M | 17.5M | 23.8M | 19.5M | 18.6M | 4.51M | 37.2K | 339.9K | 45.8K | 5.14K |
| Short-term investments | 0 | 14.5M | 0 | 0 | 0 | 0 | ||||
| Receivables | 2.15M | 2.10M | ||||||||
| Inventory | 0 | 0 | 0 | |||||||
| Current assets | 13.6M | 20.7M | 24.0M | 34.0M | 18.8M | 4.61M | 413.0K | 674.1K | 45.8K | 5.14K |
| Property, plant and equipment | 80.8K | 118.3K | 0 | 0 | 0 | |||||
| Goodwill | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K | 345.7K |
| Total assets | 14.3M | 21.6M | 25.2M | 35.1M | 20.1M | 6.05M | 2.08M | 2.57M | 2.18M | 2.36M |
| Accounts payable | 3.70M | 2.20M | 3.59M | 3.48M | 2.44M | 996.4K | 1.26M | 443.5K | 884.2K | 471.0K |
| Current liabilities | 3.80M | 2.27M | 9.35M | 14.5M | 4.17M | 996.4K | 23.5M | 443.5K | 1.24M | 631.0K |
| Long-term debt | 5.23M | 12.1M | 62.5K | 0 | 825.9K | 575.9K | ||||
| Total debt | 275.4B | 349.9K | 6.11M | 14.4M | 12.3M | 62.5K | 825.9K | 35.0K | ||
| Total liabilities | 3.98M | 2.55M | 9.70M | 19.8M | 16.4M | 996.4K | 23.6M | 443.5K | 2.06M | 1.21M |
| Shareholders' equity | 10.3M | 19.0M | 15.5M | 15.3M | 3.67M | 5.05M | -21.5M | 2.13M | 111.2K | 1.16M |
| Shares outstanding | 7.54M | 1.91M | 619.0K | 3.64M | 25.0M | 22.3M | 5.20M | 4.06M | 98.5M | 91.9M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19.0M | -19.0M | -27.9M | -40.3M | -19.0M | -10.5M | -1.63M | -2.50M | -621.3K | -623.6K |
| Capital spending | 0 | -5 | -4 | 0 | 0 | -3 | 0 | 0 | 0 | 0 |
| Free cash flow | -19.0B | -19.0M | -27.9M | -40.3M | -19.0M | -10.5M | -1.63M | -2.50M | -621.3K | -623.6K |
| Cash from investing | 14.5M | -14.3M | -14.3M | -14.3M | -14.3M | 0 | 0 | 0 | ||
| Cash from financing | 10.5M | 12.7M | 17.8M | 55.4M | 33.1M | 14.9M | 1.33M | 2.80M | 662.0K | 505.0K |
| Dividends paid | -369.5B | -886.4K | -53.6M | -17.1M | -48.7K | 0 | 0 | |||
| Share buybacks | 18.5M | -1.10M | 0 | 0 | ||||||
| Change in cash | -8.57M | -6.30M | 4.38M | 819.2K | 14.1M | 4.47M | -302.7K | 294.1K | 40.7K | -118.6K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| D | Nov 18, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 18, 2026 | Offer document | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B5 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 11, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2026 | Big-stake notice | SEC |
| S-1/A · Registration statement, amended | Aug 14, 2026 | Offer document | SEC |
| 10-K · Annual report | Aug 12, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| FWP · Free writing prospectus | Aug 7, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Aug 6, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Aug 6, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Aug 6, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| S-1/A · Registration statement, amended | Jul 31, 2026 | Offer document | SEC |
| S-1 · Registration statement | Jul 17, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 30, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 18, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Jun 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 25, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 25, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 12, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Oct 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 27, 2025 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Oct 3, 2025 | Offer document | SEC |
| POS EX | Oct 3, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Oct 3, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 25, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Aug 15, 2025 | Annual report | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 8, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 8, 2025 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Aug 7, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Aug 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 4, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 4, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 23, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 22, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 11, 2025 | Offer document | SEC |
| S-1 · Registration statement | Jul 3, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 27, 2025 | Current report | SEC |
| 8-K · Current report | Jun 24, 2025 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jun 2, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | May 20, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | May 14, 2025 | Other filings | SEC |
| DRS · Draft registration statement | May 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 8, 2025 | Meeting notice | SEC |
| PRE 14C | May 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 28, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 11, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 1-A | Dec 31, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 2, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 29, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Nov 27, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Nov 26, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 22, 2024 | Offer document | SEC |
| S-1 · Registration statement | Nov 21, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| 424B5 · Prospectus | Oct 29, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Oct 25, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| 424B5 · Prospectus | Oct 24, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 24, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| 424B5 · Prospectus | Oct 22, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 22, 2024 | Material contract | SEC |
| DEFA14A · Additional proxy material | Oct 21, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Sep 30, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 27, 2024 | Meeting notice | SEC |
| 424B5 · Prospectus | Sep 25, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 25, 2024 | Current report | SEC |
| 424B5 · Prospectus | Sep 24, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Sep 24, 2024 | Current report | SEC |
| 8-K · Current report | Sep 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 23, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Sep 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 20, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 6, 2024 | Current report | SEC |
| 8-K · Current report | Aug 1, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jul 30, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 25, 2024 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jun 17, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 7, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 19, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 13, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Mar 4, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 4, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 4, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 1, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 1, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Feb 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| 8-K · Current report | Jan 19, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 1, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 25, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 29, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 29, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Aug 28, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 25, 2023 | Other filings | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 24, 2023 | Other filings | SEC |
| S-3 · Registration statement | Aug 18, 2023 | Offer document | SEC |
| 10-K · Annual report | Aug 16, 2023 | Annual report | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 424B3 · Prospectus | Apr 14, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 7, 2023 | Other filings | SEC |
| 4 · Change in ownership | Apr 6, 2023 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 6, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 6, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 6, 2023 | Other filings | SEC |
| S-3 · Registration statement | Mar 31, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 23, 2023 | Current report | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 10, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 7, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Mar 6, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
This page holds 200 of 515 filings. Open Filings
Cap table
Built by 6ix from BioVie Inc.’s releases · as of Nov 5, 2026
- Common shares
- 10,724,724
- Fully diluted
- 16,724,724
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 10,724,724 | Nov 5, 2026 |
| Warrants | 6,000,000 | Aug 11, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.50 · expire about Aug 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 10,724,724 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cuong Do Other companies: Adagene, Inc. (Independent Director · Since at least Mar 18, 2026); Spark I Acquisition Corp. (Director · Oct 5, 2023 – Oct 5, 2023 · Past); Merck & Company, Inc. (EVP & Chief Strategy Officer · Oct 3, 2011 – May 6, 2013 · Past); TE Connectivity plc (SVP, Corp. Strategy & Bus. Dev · Jun 16, 2010 – Sep 15, 2011 · Past) | President & Chief Executive Officer · Since at least Jul 1, 2018 |
| James Paul Lang Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Dec 4, 2025); OptimizeRx Corporation (Director · Since at least Sep 30, 2019) | Director · Since at least Jun 30, 2020 |
| Emily Daniele Other companies: Halozyme Therapeutics, Inc. (Chief Operating Officer · Dec 17, 2025 – Nov 5, 2026 · Past) | Chief Operating Officer · Dec 17, 2025 – Nov 5, 2026 · Past |
| Jim Lang Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Dec 8, 2025) | Independent Director · Since at least Dec 17, 2025 |
| Amy Chappell | Independent Director · Since at least Jul 22, 2025 |
| Chris Reading | Senior Vice President Alzheimer's Disease Program · Since at least Nov 4, 2026 |
| Christopher Reading | EVP Neuroscience R&D · Jul 1, 2021 – Feb 16, 2023 · Past |
| Clarence Ahlem | Senior Vice President Operations · Since at least Oct 20, 2026 |
| David Morse | Chief Regulatory Officer and Senior Vice President · Since at least Nov 5, 2026 |
| Jonathan M Adams | EVP Liver Cirrhosis Programs · Jun 30, 2020 – Feb 2, 2022 · Past |
All 16 people
| Person | Seat |
|---|---|
| Joseph M. Palumbo | Executive Vice President, Research & Development and Chief Medical Officer · Since at least Aug 28, 2026 |
| Kameel Farag | Independent Director · Since at least Jul 22, 2025 |
| Michael Sherman | Independent Director · Since at least Nov 5, 2026 |
| Penelope Markham | Senior Vice President Liver Disease and Long COVID Programs · Since at least Nov 2, 2026 |
| Sig Rogich | Independent Director · Since at least Nov 5, 2026 |
| Wendy Kim | Chief Financial Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BioVie Inc.